NOVAVAX INC Capital Expenditures
NOVAVAX INC (NVAX) reported Capital Expenditures of $66.03 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2022-11-09
- 2022-09-30: Payments to Acquire Property, Plant, and Equipment 9 month $66.03M.
- 2021-09-30: Payments to Acquire Property, Plant, and Equipment 9 month $41.12M.
| Period end | Payments to Acquire Property, Plant, and Equipment 9 month |
|---|---|
| 2022-09-30 | $66.03M 10-Q · filed 2022-11-09 |
| 2021-09-30 | $41.12M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |